Chemical Compound Review:
LS-172913 8-ethyl-3,5-dimethyl-9-[4-[2- (2H-tetrazol...
Synonyms:
PDSP1_000578, PDSP2_000576, AC1L3XF7, L-158,809, C23H21N7, ...
- Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. Benigni, A., Tomasoni, S., Gagliardini, E., Zoja, C., Grunkemeyer, J.A., Kalluri, R., Remuzzi, G. J. Am. Soc. Nephrol. (2001)
- AT1 receptor antagonist treatment caused persistent arterial functional changes in young spontaneously hypertensive rats. Gillies, L.K., Lu, M., Wang, H., Lee, R.M. Hypertension (1997)
- Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits. Li, Y.L., Xia, X.H., Zheng, H., Gao, L., Li, Y.F., Liu, D., Patel, K.P., Wang, W., Schultz, H.D. Cardiovasc. Res. (2006)
- Temporal regression of myocyte hypertrophy in hypertensive, heart failure-prone rats treated with an AT1-receptor antagonist. Tamura, T., Said, S., Andersen, S.M., McCune, S.A., Mochizuki, S., Gerdes, A.M. J. Card. Fail. (2002)
- Effect of the novel angiotensin II type 1 receptor antagonist L-158,809 on acute infarct expansion and acute anterior myocardial infarction in the dog. Ford, W.R., Khan, M.I., Jugdutt, B.I. The Canadian journal of cardiology. (1998)
- Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis. Huckle, W.R., Drag, M.D., Acker, W.R., Powers, M., McFall, R.C., Holder, D.J., Fujita, T., Stabilito, I.I., Kim, D., Ondeyka, D.L., Mantlo, N.B., Chang, R.S., Reilly, C.F., Schwartz, R.S., Greenlee, W.J., Johnson, R.G. Circulation (1996)
- Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor. Perlman, S., Schambye, H.T., Rivero, R.A., Greenlee, W.J., Hjorth, S.A., Schwartz, T.W. J. Biol. Chem. (1995)
- Photoaffinity labeling of subtype 2 angiotensin receptor of human myometrium. Servant, G., Boulay, G., Bossé, R., Escher, E., Guillemette, G. Mol. Pharmacol. (1993)
- Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade. Hayashida, W., Donckier, J., Van Mechelen, H., Charlier, A.A., Pouleur, H. Cardiovasc. Res. (1997)
- Angiotensin II receptor antagonist, L-158,809, prevents intimal hyperplasia in dog grafted veins. Yuda, A., Takai, S., Jin, D., Sawada, Y., Nishimoto, M., Matsuyama, N., Asada, K., Kondo, K., Sasaki, S., Miyazaki, M. Life Sci. (2000)
- Renoprotective mechanisms of angiotensin II antagonism in experimental chronic renal failure. Uhlenius, N., Miettinen, A., Vuolteenaho, O., Tikkanen, I. Kidney Blood Press. Res. (2002)
- Inducible nitric oxide synthase (iNOS) expression is increased in lipopolysaccharide (LPS)-stimulated diabetic rat glomeruli: effect of ACE inhibitor and angiotensin II receptor blocker. Lee, H.Y., Noh, H.J., Gang, J.G., Xu, Z.G., Jeong, H.J., Kang, S.W., Choi, K.H., Han, D.S. Yonsei Med. J. (2002)
- Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension. Gillies, L.K., Werstiuk, E.S., Lee, R.M. J. Hypertens. (1998)
- Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure. Shen, Y.T., Wiedmann, R.T., Greenland, B.D., Lynch, J.J., Grossman, W. Cardiovasc. Res. (1998)
- AT2-antagonist sensitive potentiation of angiotensin II-induced vasoconstrictions by blockade of nitric oxide synthesis in rat renal vasculature. Muller, C., Endlich, K., Barthelmebs, M., Helwig, J.J. Br. J. Pharmacol. (1997)
- Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. Jaiswal, N., Tallant, E.A., Jaiswal, R.K., Diz, D.I., Ferrario, C.M. J. Pharmacol. Exp. Ther. (1993)
- Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Li, X., Zhang, H., Soledad-Conrad, V., Zhuang, J., Uhal, B.D. Am. J. Physiol. Lung Cell Mol. Physiol. (2003)
- Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Xu, Z.G., Yoo, T.H., Ryu, D.R., Cheon Park, H., Ha, S.K., Han, D.S., Adler, S.G., Natarajan, R., Kang, S.W. Kidney Int. (2005)
- Cardiac interstitial fluid levels of angiotensin I and II in the pig. Schuijt, M.P., van Kats, J.P., de Zeeuw, S., Duncker, D.J., Verdouw, P.D., Schalekamp, M.A., Danser, A.H. J. Hypertens. (1999)
- Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist. Moulder, J.E., Fish, B.L., Cohen, E.P. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. (1998)
- Influence of surface properties at biodegradable microsphere surfaces: effects on plasma protein adsorption and phagocytosis. Lacasse, F.X., Filion, M.C., Phillips, N.C., Escher, E., McMullen, J.N., Hildgen, P. Pharm. Res. (1998)
- Effects of chronic blockade of angiotensin II receptor on the maintenance of hypertension and vascular changes in spontaneously hypertensive rats. Gillies, L.K., Lee, R.M. Can. J. Physiol. Pharmacol. (1996)
- In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. Chang, R.S., Siegl, P.K., Clineschmidt, B.V., Mantlo, N.B., Chakravarty, P.K., Greenlee, W.J., Patchett, A.A., Lotti, V.J. J. Pharmacol. Exp. Ther. (1992)
- Disposition of the angiotensin II receptor antagonist L-158,809 in rats and rhesus monkeys. Colletti, A.E., Krieter, P.A. Drug Metab. Dispos. (1994)
- Angiotensin II binding sites on micro-organisms contaminating cell cultures. Whitebread, S., Pfeilschifter, J., Ramjoué, H., de Gasparo, M. Regul. Pept. (1993)
- Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Moulder, J.E., Fish, B.L., Cohen, E.P., Bonsib, S.M. Radiat. Res. (1996)
- Angiotensin II regulates 11beta-hydroxysteroid dehydrogenase type 2 via AT2 receptors. Lanz, B., Kadereit, B., Ernst, S., Shojaati, K., Causevic, M., Frey, B.M., Frey, F.J., Mohaupt, M.G. Kidney Int. (2003)
- In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. Siegl, P.K., Chang, R.S., Mantlo, N.B., Chakravarty, P.K., Ondeyka, D.L., Greenlee, W.J., Patchett, A.A., Sweet, C.S., Lotti, V.J. J. Pharmacol. Exp. Ther. (1992)
- Improved activity of a new angiotensin receptor antagonist by an injectable spray-dried polymer microsphere preparation. Lacasse, F.X., Hildgen, P., Pérodin, J., Escher, E., Phillips, N.C., McMullen, J.N. Pharm. Res. (1997)
- Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Lee, E.Y., Shim, M.S., Kim, M.J., Hong, S.Y., Shin, Y.G., Chung, C.H. Exp. Mol. Med. (2004)